Litigation Details for Teva Pharmaceuticals International GmbH v. Eli Lilly and Company (D. Mass. 2018)
✉ Email this page to a colleague
Teva Pharmaceuticals International GmbH v. Eli Lilly and Company (D. Mass. 2018)
| Docket | ⤷ Sign Up | Date Filed | 2018-09-27 |
| Court | District Court, D. Massachusetts | Date Terminated | 2023-09-28 |
| Cause | 35:271 Patent Infringement | Assigned To | Allison Dale Burroughs |
| Jury Demand | Both | Referred To | |
| Patents | 8,586,045 | ||
| Link to Docket | External link to docket | ||
Biologic Drugs cited in Teva Pharmaceuticals International GmbH v. Eli Lilly and Company
The biologic drug covered by the patent cited in this case is ⤷ Sign Up .
Details for Teva Pharmaceuticals International GmbH v. Eli Lilly and Company (D. Mass. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2018-09-27 | 1 | THE PATENTS-IN-SUIT A. U.S. Patent No. 8,586,045 46. On November…November 19, 2013, United States Patent No. 8,586,045 (“the ’045 patent”), …innovations are protected by at least U.S. Patent Nos. 8,586,045; 8,597,649; 9,266,951; 9,340,614; 9,346,881…9,890,210; and 9,890,211 (“the Patents-in-Suit”). Labrys assigned the Patents-in-Suit to Teva on September…Infringes The Patents-in-Suit. 26. Eli Lilly tracks and follows Teva’s patents related to the | External link to document | |
| 2021-02-24 | 101 | Memorandum & Order | nine patents: U.S. Patent Nos. 8,586,045 (“the ’045 patent”); 8,597,649 (“the ’649 patent”); 9,…9,266,951 (“the ’951 patent”); 9,340,614 (“the ’614 patent”); 9,346,881 (“the ’881 patent”); 9,884,907 …9,884,907 (“the ’907 patent”); 9,884,908 (“the ’908 patent”); 9,890,210 (“the ’210 patent”); and 9,890,211 …migraines, does not infringe Teva’s patents and that Teva’s patents are invalid. [ECF No. 17]. The parties…9,890,211 (“the ’211 patent”). [ECF No. 65 at 7, 8 n.3; ECF No. 66 at 6]. Six of the patents claim as inventive | External link to document |
| 2022-01-11 | 251 | Memorandum & Order | has infringed Teva’s patents, including U.S. Patent Nos. 8,586,045 (the “’045 Patent”); 9,884,907 (the …the “’907 Patent”); and 9,884,908 (the “’908 Patent”) (collectively, the “patents-in-suit”). [ECF No. 1…MEMORANDUM AND ORDER BURROUGHS, D.J. In this patent infringement suit, Teva Pharmaceuticals International… 1]. The patents-in- suit are related to a treatment for migraines that is marketed under the brand name…discussions of topics that “have no relation to the patents-in-suit or this litigation” are not evidence | External link to document |
| 2022-03-28 | 289 | Summary Judgment | to all asserted claims of the patents-in- suit (U.S. Patent No. 8,586,045, claims 17, 18, 19, 20, 21, …27, and 30; U.S. Patent No. 9,884,907, claims 1, 4, 5, 6, 15, and 17; and U.S. Patent No. 9,884,907, claims…, 5, 6, 15, and 17). The specification of the patents-in-suit does not, as a matter of law, enable a … 28 September 2023 1:18-cv-12029 830 Patent Both District Court, D. Massachusetts | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
